

Key characteristics analysis of migraine clinical trials, from 2016 to 2025: a cross-sectional study

INPLASY202630083

doi: 10.37766/inplasy2026.3.0083

Received: 23 March 2026

Published: 23 March 2026

Corresponding author:

Yicheng Gao

gaoyicheng@ynucm.edu.cn

Author Affiliation:

Yunnan University of Chinese Medicine, kunming, China.

Yin, XJ; Sun, YZ; Liu, SY; Ye, Z; Rao, CR; Lu, J; He, GJ; Zong, X; Su, XJ; Luo, Y; Jiang, MG; Zhao, MX; Ye, W.

ADMINISTRATIVE INFORMATION**Support** - This work was supported by Yunnan Province's Xingdian Talents Support Program Young Scholars [grant numbers: XDYC-QNRC-2022-0269]. Funding sources have no involvement in any of the activities conducted in this article.**Review Stage at time of this submission** - Preliminary searches.**Conflicts of interest** - None declared.**INPLASY registration number:** INPLASY202630083**Amendments** - This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 23 March 2026 and was last updated on 23 March 2026.**INTRODUCTION**

Review question / Objective A systematic review of interventional clinical trials for migraine over the past decade was conducted, focusing on the analysis of study design, interventions, and outcomes.

Condition being studied Migraine is a common chronic, episodic, brain dysfunction disorder. Long-term, recurrent attacks can lead to severe health loss, reduced quality of life, and productivity decline, making it one of the major global public health issues. The quality of published interventional clinical trials has been inconsistent, with diverse interventions and outcomes involved. This study conducts a systematic analysis of these clinical trials to provide references for future migraine clinical trial research.

METHODS**Participant or population** Migraine patients.**Intervention** Not applicable.**Comparator** Not applicable.**Study designs to be included** Clinical trials..**Eligibility criteria** Inclusion criteria: (1) interventional clinical trials; (2) published articles; (3) published in English. Exclusion criteria: (1) Research protocol.**Information sources** PubMed, Embase, Cochrane Library.**Main outcome(s)** Not applicable.

Quality assessment / Risk of bias analysis Not applicable.

Strategy of data synthesis Descriptive statistics were used, and the proportion of the items was calculated.

Subgroup analysis Not applicable.

Sensitivity analysis Not applicable.

Country(ies) involved All authors are from China.

Keywords Headache; Clinical trials; Systematic review; Randomized controlled trial.

Contributions of each author

Author 1 - Xuejian Yin.

Email: yinxuejian@ynucm.edu.cn

Author 2 - Yuze Sun.

Email: sunyuze@ynucm.edu.cn

Author 3 - Shiyi Liu.

Email: 19982908616@163.com

Author 4 - Zuo Ye.

Author 5 - Chengrong Rao.

Author 6 - Juan Lu.

Author 7 - Guojing He.

Author 8 - Xue Zong.

Author 9 - Xuejuan Su.

Author 10 - Ying Luo.

Author 11 - Muguo Jiang.

Author 12 - Mengxi Zhao.

Author 13 - Wenkan Ye.

Author 14 - Yicheng Gao.

Email: gaoyicheng@ynucm.edu.cn

Author 15 - Kai Yuan.

Email: yk_ynutcm@163.com